

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Adalimumab for the treatment of psoriasis

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Abbott Laboratories Ltd (adalimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Changing Faces • Psoriasis Association • Psoriatic Arthropathy Alliance • Skin Care Campaign • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association of Dermatologists • British Dermatological Nursing Group • British Skin Foundation • British Society of Rehabilitation Medicine • Community Practitioners' & Health Visitors Association • National Association of Primary Care • Primary Care Dermatology Society • Royal College of General Practitioners • Royal Society of Medicine - Forum on Intellectual Disabilities • Royal College of Nursing • Royal College of Physicians • Royal College of Physicians of Edinburgh • Royal Pharmaceutical Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Kirklees PCT • Nottinghamshire County PCT • Welsh Assembly Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency (MHRA) • National Public Health Service for Wales • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Crawford Pharmaceuticals (psoralen) • Mayne Pharma Plc (methotrexate) • Novartis Pharmaceuticals UK Ltd (ciclosporin) • Pfizer Ltd (methotrexate) • Roche Products Ltd (acitretin) • Schering-Plough Ltd (infliximab) • Serono Ltd (efalizumab) • Wockhardt UK Ltd (methotrexate) • Wyeth Pharmaceuticals (etanercept) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Centre of Evidence-based Dermatology, University of Nottingham • MRC Clinical Trials Unit • Skin Research Centre, University of Leeds • Skin Treatment and Research Trust (START)

National Institute for Health and Clinical Excellence
 Consultation on the provisional matrix for the proposed appraisal of adalimumab for the treatment of psoriasis

Consultees	Commentators (no right to submit or appeal)
	<u>Evidence Review Group</u> <ul style="list-style-type: none">• Assessment group tbc• National Coordinating Centre for Health Technology Assessment

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.